TNGXTango Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $62M
- 48% YoY
- Operating margin
- -178.4%
- 48% YoY
- EBITDA
- −$109M
- 24% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired42% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $37M | $25M | $37M | $42M | $62M | 48% |
| Operating income | −$58M | −$111M | −$114M | −$146M | −$111M | 24% |
| Net income | −$58M | −$108M | −$102M | −$130M | −$102M | 22% |
| Operating cash flow | −$60M | −$109M | −$118M | −$132M | −$139M | 5.6% |
| Capex | $2M | $8M | $2M | $754K | $1M | 39% |
| Stock-based comp | $8M | $14M | $19M | $29M | $26M | 8.5% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $859K · 5
- Net
- −$859K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $10M | — | — |
| FY2024 | $7M | −$3M | — | — |
| FY2023 | $3M | $8M | — | — |